Phase I and clinical pharmacological evaluation of aphidicolin glycinate

Cristiana Sessa, Massimo Zucchetti, Enrico Davoli, Raffaele Califano, Franco Cavalli, Sergio Frustaci, Lindsey Gumbrell, Aaron Sulkes, Benjamin Winograd, Maurizio D'Incalci

Research output: Contribution to journalArticle

Abstract

The toxicity profile and the pharmacokinetics of aphidicolin glycinate, a water-soluble analogue of aphidicolin, have been evaluated in two consecutive phase I clinical studies. In the first study, aphidicolin glycinate was given by 1-hour infusion for 5 consecutive days, every 3 weeks (daily x 5 study); in the second study, which was planned on the basis of the pharmacokinetic information obtained in the previous study, the drug was given by 24-hour continuous infusion. Treatment was repeated every 3 weeks. In the daily x 5 study, the daily dose was escalated from 12 mg/m2 to the maximum tolerated dose of 2250 mg/m2. Local toxicity was dose limiting. Elimination half-life was 2 ± 0.2 hours (mean ± SE),. with aphidicolin being undetectable 6-8 hours after the end of the infusion. In the 24-hour continuous-infusion study, the dose was escalated from 435 mg/m2 to the maximum tolerated dose of 4500 mg/m2. Local toxicity was dose limiting, while other toxic effects were absent. The experimentally determined concentrations at the steady state were in agreement with those predicted on the basis of the available pharmacokinetic data. The targeted concentration at the steady state of 3 μg/mL was achieved at doses greater than or equal to 3000 mg/m2. Twenty-four-hour continuous infusion is the recommended schedule for clinical evaluations of aphidicolin glycinate as the synchronizing agent or in combination with cisplatin.

Original languageEnglish
Pages (from-to)1160-1164
Number of pages5
JournalJournal of the National Cancer Institute
Volume83
Issue number16
Publication statusPublished - Aug 21 1991

Fingerprint

Pharmacokinetics
Aphidicolin
Toxicity
Dose
Maximum Tolerated Dose
Pharmacology
Evaluation
Poisons
Consecutive
Cisplatin
Limiting
Half-Life
Appointments and Schedules
Water
Elimination
Drugs
Schedule
Pharmaceutical Preparations
aphidicolin glycinate
Analogue

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Physiology (medical)
  • Radiology Nuclear Medicine and imaging

Cite this

Phase I and clinical pharmacological evaluation of aphidicolin glycinate. / Sessa, Cristiana; Zucchetti, Massimo; Davoli, Enrico; Califano, Raffaele; Cavalli, Franco; Frustaci, Sergio; Gumbrell, Lindsey; Sulkes, Aaron; Winograd, Benjamin; D'Incalci, Maurizio.

In: Journal of the National Cancer Institute, Vol. 83, No. 16, 21.08.1991, p. 1160-1164.

Research output: Contribution to journalArticle

Sessa, C, Zucchetti, M, Davoli, E, Califano, R, Cavalli, F, Frustaci, S, Gumbrell, L, Sulkes, A, Winograd, B & D'Incalci, M 1991, 'Phase I and clinical pharmacological evaluation of aphidicolin glycinate', Journal of the National Cancer Institute, vol. 83, no. 16, pp. 1160-1164.
Sessa, Cristiana ; Zucchetti, Massimo ; Davoli, Enrico ; Califano, Raffaele ; Cavalli, Franco ; Frustaci, Sergio ; Gumbrell, Lindsey ; Sulkes, Aaron ; Winograd, Benjamin ; D'Incalci, Maurizio. / Phase I and clinical pharmacological evaluation of aphidicolin glycinate. In: Journal of the National Cancer Institute. 1991 ; Vol. 83, No. 16. pp. 1160-1164.
@article{8a69d2ef832e4787985526a0b38d4245,
title = "Phase I and clinical pharmacological evaluation of aphidicolin glycinate",
abstract = "The toxicity profile and the pharmacokinetics of aphidicolin glycinate, a water-soluble analogue of aphidicolin, have been evaluated in two consecutive phase I clinical studies. In the first study, aphidicolin glycinate was given by 1-hour infusion for 5 consecutive days, every 3 weeks (daily x 5 study); in the second study, which was planned on the basis of the pharmacokinetic information obtained in the previous study, the drug was given by 24-hour continuous infusion. Treatment was repeated every 3 weeks. In the daily x 5 study, the daily dose was escalated from 12 mg/m2 to the maximum tolerated dose of 2250 mg/m2. Local toxicity was dose limiting. Elimination half-life was 2 ± 0.2 hours (mean ± SE),. with aphidicolin being undetectable 6-8 hours after the end of the infusion. In the 24-hour continuous-infusion study, the dose was escalated from 435 mg/m2 to the maximum tolerated dose of 4500 mg/m2. Local toxicity was dose limiting, while other toxic effects were absent. The experimentally determined concentrations at the steady state were in agreement with those predicted on the basis of the available pharmacokinetic data. The targeted concentration at the steady state of 3 μg/mL was achieved at doses greater than or equal to 3000 mg/m2. Twenty-four-hour continuous infusion is the recommended schedule for clinical evaluations of aphidicolin glycinate as the synchronizing agent or in combination with cisplatin.",
author = "Cristiana Sessa and Massimo Zucchetti and Enrico Davoli and Raffaele Califano and Franco Cavalli and Sergio Frustaci and Lindsey Gumbrell and Aaron Sulkes and Benjamin Winograd and Maurizio D'Incalci",
year = "1991",
month = "8",
day = "21",
language = "English",
volume = "83",
pages = "1160--1164",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "16",

}

TY - JOUR

T1 - Phase I and clinical pharmacological evaluation of aphidicolin glycinate

AU - Sessa, Cristiana

AU - Zucchetti, Massimo

AU - Davoli, Enrico

AU - Califano, Raffaele

AU - Cavalli, Franco

AU - Frustaci, Sergio

AU - Gumbrell, Lindsey

AU - Sulkes, Aaron

AU - Winograd, Benjamin

AU - D'Incalci, Maurizio

PY - 1991/8/21

Y1 - 1991/8/21

N2 - The toxicity profile and the pharmacokinetics of aphidicolin glycinate, a water-soluble analogue of aphidicolin, have been evaluated in two consecutive phase I clinical studies. In the first study, aphidicolin glycinate was given by 1-hour infusion for 5 consecutive days, every 3 weeks (daily x 5 study); in the second study, which was planned on the basis of the pharmacokinetic information obtained in the previous study, the drug was given by 24-hour continuous infusion. Treatment was repeated every 3 weeks. In the daily x 5 study, the daily dose was escalated from 12 mg/m2 to the maximum tolerated dose of 2250 mg/m2. Local toxicity was dose limiting. Elimination half-life was 2 ± 0.2 hours (mean ± SE),. with aphidicolin being undetectable 6-8 hours after the end of the infusion. In the 24-hour continuous-infusion study, the dose was escalated from 435 mg/m2 to the maximum tolerated dose of 4500 mg/m2. Local toxicity was dose limiting, while other toxic effects were absent. The experimentally determined concentrations at the steady state were in agreement with those predicted on the basis of the available pharmacokinetic data. The targeted concentration at the steady state of 3 μg/mL was achieved at doses greater than or equal to 3000 mg/m2. Twenty-four-hour continuous infusion is the recommended schedule for clinical evaluations of aphidicolin glycinate as the synchronizing agent or in combination with cisplatin.

AB - The toxicity profile and the pharmacokinetics of aphidicolin glycinate, a water-soluble analogue of aphidicolin, have been evaluated in two consecutive phase I clinical studies. In the first study, aphidicolin glycinate was given by 1-hour infusion for 5 consecutive days, every 3 weeks (daily x 5 study); in the second study, which was planned on the basis of the pharmacokinetic information obtained in the previous study, the drug was given by 24-hour continuous infusion. Treatment was repeated every 3 weeks. In the daily x 5 study, the daily dose was escalated from 12 mg/m2 to the maximum tolerated dose of 2250 mg/m2. Local toxicity was dose limiting. Elimination half-life was 2 ± 0.2 hours (mean ± SE),. with aphidicolin being undetectable 6-8 hours after the end of the infusion. In the 24-hour continuous-infusion study, the dose was escalated from 435 mg/m2 to the maximum tolerated dose of 4500 mg/m2. Local toxicity was dose limiting, while other toxic effects were absent. The experimentally determined concentrations at the steady state were in agreement with those predicted on the basis of the available pharmacokinetic data. The targeted concentration at the steady state of 3 μg/mL was achieved at doses greater than or equal to 3000 mg/m2. Twenty-four-hour continuous infusion is the recommended schedule for clinical evaluations of aphidicolin glycinate as the synchronizing agent or in combination with cisplatin.

UR - http://www.scopus.com/inward/record.url?scp=0025742877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025742877&partnerID=8YFLogxK

M3 - Article

C2 - 1886148

AN - SCOPUS:0025742877

VL - 83

SP - 1160

EP - 1164

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 16

ER -